Ambrx Biopharma Inc. (NYSE:AMAM – Get Rating)'s share price rose 3.6% during mid-day trading on Friday . The stock traded as high as $2.02 and last traded at $1.99. Approximately 163,413 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 964,432 shares. The stock had previously closed at $1.92.
Wall Street Analysts Forecast Growth
Separately, Robert W. Baird dropped their price objective on shares of Ambrx Biopharma from $8.00 to $4.00 in a research report on Wednesday, October 19th.
Get Ambrx Biopharma alerts:Ambrx Biopharma Trading Up 3.6 %
The stock's fifty day moving average is $1.53 and its two-hundred day moving average is $1.65.
Institutional Investors Weigh In On Ambrx Biopharma
Large investors have recently added to or reduced their stakes in the company. FMR LLC grew its holdings in Ambrx Biopharma by 0.8% during the 2nd quarter. FMR LLC now owns 3,857,679 shares of the company's stock valued at $10,223,000 after purchasing an additional 32,320 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Ambrx Biopharma by 91.5% during the 1st quarter. Renaissance Technologies LLC now owns 22,600 shares of the company's stock valued at $93,000 after acquiring an additional 10,800 shares during the last quarter. Finally, Royal Bank of Canada bought a new position in Ambrx Biopharma during the 3rd quarter valued at $46,000. 43.14% of the stock is owned by institutional investors and hedge funds.About Ambrx Biopharma
(Get Rating)
Ambrx Biopharma Inc, a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer.
Further Reading
- Get a free copy of the StockNews.com research report on Ambrx Biopharma (AMAM)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Ambrx Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambrx Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.